Beryl Drugs Ltd. (BSE: 524606) is an Indore, Madhya Pradesh-based company in the Pharmaceutical Contract Manufacturing Services industry. With a market capitalisation of ₹12 Cr, it ranks #4,696 by market cap among the 6,197 Indian listed companies on FinBizNet, and #25 of 26 in Pharmaceutical Contract Manufacturing Services. At ₹25.00 (as of 16 Nov 2026), the share price is 16.4% below its 52-week high of ₹29.90 and 57.0% above its 52-week low of ₹15.92. The share price is up 5.0% over one year and up 4.7% over three months.
| Current Price | ₹25.00 |
|---|---|
| Market Cap | ₹12 Cr |
| BSE Code | 524606 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | 28.7 |
| Return on Equity | 4.38% |
| Return on Assets | 3.69% |
| 52-Week Range | ₹15.92 – ₹29.90 |
| 1-Year Price Change | +5.0% |
| 3-Month Price Change | +4.7% |
| Beta (1Y) | 0.33 |
| Headquarters | Indore, Madhya Pradesh |
| Website | www.beryldrugs.com |
Delivery averaged 85.0% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Beryl Drugs Limited manufactures and markets pharmaceutical products in India. The company offers various branded and generic pharmaceutical formulations, bulk drugs, I.V. fluids, small volume injectables in liquid and dry powder forms, and eye and ear drops, as well as veterinary products. It also provides research and development, and contract manufacturing services. The company exports its products. Beryl Drugs Limited was incorporated in 1993 and is based in Indore, India.
1. Pharmaceutical Industry-This segment manufactures and markets generic pharmaceutical formulations in India. 2. Trading Division-This segment engages in the sale and export of branded, generic pharmaceutical formulations in India. 3. Manufacturing Division-This segment engages in the manufacture, sale, and export of branded, generic pharmaceutical formulations in India.
1. Pharmaceutical Industry-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Torrent Pharma Ltd. | ₹1,79,494 Cr | 73.6 | 16.98% | ₹4,979 Cr | +30.4% |
| Aether Industries Limited | ₹21,710 Cr | 101.8 | 9.81% | ₹347 Cr | +127.8% |
| Alivus Life Sciences Ltd | ₹17,862 Cr | 31.5 | 18.36% | ₹682 Cr | +64.0% |
| Aarti Pharmalabs Ltd | ₹8,374 Cr | 52.5 | 8.49% | ₹610 Cr | +15.4% |
| Solara Active Pharma Sciences Limited | ₹3,225 Cr | n/m | -0.63% | ₹417 Cr | +22.1% |
| Sai Parenteral's Limited | ₹2,235 Cr | 115.8 | 2.88% | ₹195 Cr | — |
| KRM Ayurveda Limited | ₹521 Cr | 25.9 | 17.54% | ₹32 Cr | — |
| Trident Lifeline Limited | ₹511 Cr | 26 | — | — | +37.6% |
| Beryl Drugs Ltd. | ₹12 Cr | 28.7 | 4.38% | — | +5.0% |
Listed by market capitalisation. Ratios are shown for context only.
Beryl Drugs Ltd. is trading at ₹25.00, with a market capitalisation of ₹12 Cr.
Beryl Drugs Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Beryl Drugs Ltd. has a P/E of 28.7 and a return on equity of 4.38%.
Beryl Drugs Ltd. is listed on the BSE under the scrip code 524606.
Beryl Drugs Ltd.'s share price is up 5.0% over one year and up 4.7% over three months. Its 52-week range is ₹15.92 to ₹29.90.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.